1. Home
  2. PEW vs IBIO Comparison

PEW vs IBIO Comparison

Compare PEW & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrabAGun Digital Holdings Inc.

PEW

GrabAGun Digital Holdings Inc.

N/A

Current Price

$1.61

Market Cap

56.7M

ML Signal

N/A

IBIO

iBio Inc.

N/A

Current Price

$0.72

Market Cap

52.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PEW
IBIO
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.7M
52.8M
IPO Year
2025
2009

Fundamental Metrics

Financial Performance
Metric
PEW
IBIO
Price
$1.61
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $5.69
AVG Volume (30 Days)
405.6K
★ 470.8K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
N/A
★ N/A
Revenue
★ $96,449,000.00
N/A
Revenue This Year
$6.38
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 3.57
N/A
52 Week Low
$1.76
$0.69
52 Week High
$3.97
$3.82

Technical Indicators

Market Signals
Indicator
PEW
IBIO
Relative Strength Index (RSI) 25.68 37.67
Support Level N/A $0.71
Resistance Level $2.20 $0.85
Average True Range (ATR) 0.12 0.06
MACD -0.03 0.01
Stochastic Oscillator 0.70 16.94

Price Performance

Historical Comparison
PEW
IBIO

About PEW GrabAGun Digital Holdings Inc.

GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: